{
  "directed": true,
  "graph": {
    "annotation_curie": [],
    "annotation_list": {
      "MeasurementRelation": [
        "=",
        "~"
      ],
      "MeasurementType": [
        "CSF concentration",
        "IC50",
        "brain concertration",
        "dose",
        "plasma concentration"
      ],
      "MeasurementUnits": [
        "mg",
        "μM"
      ]
    },
    "annotation_miriam": [],
    "annotation_pattern": {
      "ArticleCompoundNumber": ".*",
      "Figure": ".*",
      "MeasurementRangeLower": ".*",
      "MeasurementRangeUpper": ".*",
      "MeasurementValue": ".*",
      "Page": ".*",
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "document_metadata": {
      "authors": "Lingling Xu",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-b peptide and s levels: target engagement, tolerability and pharmacokinetics in humans",
      "version": "0.1.0"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "PUBCHEM": "^\\d+$",
      "TAXONOMY": "^\\d+$",
      "UNIPROT": "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\\.\\d+)?$"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "CONSO": "https://raw.githubusercontent.com/pharmacome/conso/501ceccdc9a27d97edbdc48a89ebe8e1dd3626e9/export/conso-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns",
      "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns",
      "MGI": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
      "PFAM": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
      "RGD": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns"
    },
    "path": "app/maccecchini2012.bel",
    "pybel_version": "0.15.3"
  },
  "links": [
    {
      "annotations": {
        "ArticleCompoundNumber": [
          {
            "identifier": "1",
            "namespace": "ArticleCompoundNumber"
          }
        ],
        "Confidence": [
          {
            "identifier": "High",
            "namespace": "Confidence"
          }
        ],
        "Figure": [
          {
            "identifier": "2A",
            "namespace": "Figure"
          }
        ],
        "MeasurementType": [
          {
            "identifier": "dose",
            "namespace": "MeasurementType"
          }
        ],
        "MeasurementUnits": [
          {
            "identifier": "mg",
            "namespace": "MeasurementUnits"
          }
        ],
        "MeasurementValue": [
          {
            "identifier": "160",
            "namespace": "MeasurementValue"
          }
        ],
        "Page": [
          {
            "identifier": "896",
            "namespace": "Page"
          }
        ]
      },
      "citation": {
        "article_type": "Journal Article",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "identifier": "22791904",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "namespace": "pubmed",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": "A 160 mg dose was associated with an increased incidence of nausea and vomiting (four subjects were nauseous and three vomited)",
      "key": "3d0fc095fb4294ed5957350d6d1a7f99",
      "line": 96,
      "relation": "increases",
      "source": 0,
      "target": 9
    },
    {
      "annotations": {
        "ArticleCompoundNumber": [
          {
            "identifier": "1",
            "namespace": "ArticleCompoundNumber"
          }
        ],
        "Confidence": [
          {
            "identifier": "High",
            "namespace": "Confidence"
          }
        ],
        "MeasurementType": [
          {
            "identifier": "dose",
            "namespace": "MeasurementType"
          }
        ],
        "MeasurementUnits": [
          {
            "identifier": "mg",
            "namespace": "MeasurementUnits"
          }
        ],
        "MeasurementValue": [
          {
            "identifier": "80",
            "namespace": "MeasurementValue"
          }
        ],
        "Page": [
          {
            "identifier": "896",
            "namespace": "Page"
          }
        ]
      },
      "citation": {
        "article_type": "Journal Article",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "identifier": "22791904",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "namespace": "pubmed",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": "Posiphen 80 mg was determined as the no observed adverse effect level (table 1).",
      "key": "ff54d05b3aadc4dd3d47bf2dd45e6c66",
      "line": 109,
      "relation": "causesNoChange",
      "source": 0,
      "target": 9
    },
    {
      "annotations": {
        "ArticleCompoundNumber": [
          {
            "identifier": "1",
            "namespace": "ArticleCompoundNumber"
          }
        ],
        "Confidence": [
          {
            "identifier": "High",
            "namespace": "Confidence"
          }
        ],
        "Figure": [
          {
            "identifier": "2A",
            "namespace": "Figure"
          }
        ],
        "MeasurementType": [
          {
            "identifier": "dose",
            "namespace": "MeasurementType"
          }
        ],
        "MeasurementUnits": [
          {
            "identifier": "mg",
            "namespace": "MeasurementUnits"
          }
        ],
        "MeasurementValue": [
          {
            "identifier": "160",
            "namespace": "MeasurementValue"
          }
        ],
        "Page": [
          {
            "identifier": "896",
            "namespace": "Page"
          }
        ]
      },
      "citation": {
        "article_type": "Journal Article",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "identifier": "22791904",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "namespace": "pubmed",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": "A 160 mg dose was associated with an increased incidence of nausea and vomiting (four subjects were nauseous and three vomited)",
      "key": "d697343c242010a1bbab0da014d2150c",
      "line": 97,
      "relation": "increases",
      "source": 0,
      "target": 10
    },
    {
      "annotations": {
        "ArticleCompoundNumber": [
          {
            "identifier": "1",
            "namespace": "ArticleCompoundNumber"
          }
        ],
        "Confidence": [
          {
            "identifier": "High",
            "namespace": "Confidence"
          }
        ],
        "MeasurementType": [
          {
            "identifier": "dose",
            "namespace": "MeasurementType"
          }
        ],
        "MeasurementUnits": [
          {
            "identifier": "mg",
            "namespace": "MeasurementUnits"
          }
        ],
        "MeasurementValue": [
          {
            "identifier": "80",
            "namespace": "MeasurementValue"
          }
        ],
        "Page": [
          {
            "identifier": "896",
            "namespace": "Page"
          }
        ]
      },
      "citation": {
        "article_type": "Journal Article",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "identifier": "22791904",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "namespace": "pubmed",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": "Posiphen 80 mg was determined as the no observed adverse effect level (table 1).",
      "key": "3df21ff34b4b60bf940c409fd0e9251b",
      "line": 110,
      "relation": "causesNoChange",
      "source": 0,
      "target": 10
    },
    {
      "annotations": {
        "ArticleCompoundNumber": [
          {
            "identifier": "1",
            "namespace": "ArticleCompoundNumber"
          }
        ],
        "Confidence": [
          {
            "identifier": "High",
            "namespace": "Confidence"
          }
        ],
        "Page": [
          {
            "identifier": "899",
            "namespace": "Page"
          }
        ]
      },
      "citation": {
        "article_type": "Journal Article",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "identifier": "22791904",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "namespace": "pubmed",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": "Specifically, Posiphen lowered sAPPa and sAPPb levels by \u000159.9% and \u000157.7%, respectively, assessed by the AlpaLisa assay, and by \u000134.1% and \u000134%, respectively, assessed by the MSD assay, in accordance with Posiphen’s proposed mechanism of action to inhibit APP expression.",
      "key": "fcdbbf785e9ca33808801357f45d13c7",
      "line": 118,
      "relation": "decreases",
      "source": 0,
      "target": 1
    },
    {
      "annotations": {
        "ArticleCompoundNumber": [
          {
            "identifier": "1",
            "namespace": "ArticleCompoundNumber"
          }
        ],
        "Confidence": [
          {
            "identifier": "High",
            "namespace": "Confidence"
          }
        ],
        "Page": [
          {
            "identifier": "899",
            "namespace": "Page"
          }
        ]
      },
      "citation": {
        "article_type": "Journal Article",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "identifier": "22791904",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "namespace": "pubmed",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": "Specifically, Posiphen lowered sAPPa and sAPPb levels by \u000159.9% and \u000157.7%, respectively, assessed by the AlpaLisa assay, and by \u000134.1% and \u000134%, respectively, assessed by the MSD assay, in accordance with Posiphen’s proposed mechanism of action to inhibit APP expression.",
      "key": "0a897c746b7e51da805ceeaf1e883d73",
      "line": 119,
      "relation": "decreases",
      "source": 0,
      "target": 2
    },
    {
      "annotations": {
        "ArticleCompoundNumber": [
          {
            "identifier": "1",
            "namespace": "ArticleCompoundNumber"
          }
        ],
        "Confidence": [
          {
            "identifier": "High",
            "namespace": "Confidence"
          }
        ],
        "Page": [
          {
            "identifier": "899",
            "namespace": "Page"
          }
        ]
      },
      "citation": {
        "article_type": "Journal Article",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "identifier": "22791904",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "namespace": "pubmed",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": "In addition, Posiphen significantly reduced levels of t-s (\u000174.1%, as assessed by the Innogenetics assay and \u000146.2%, as assessed by the AlphaLisa assay) and p-s (\u000161%, as assessed by the Innogenetics assay).",
      "key": "e06ee6384e36d1cfe1b00947c42fc5c4",
      "line": 124,
      "relation": "decreases",
      "source": 0,
      "target": 7
    },
    {
      "annotations": {
        "ArticleCompoundNumber": [
          {
            "identifier": "1",
            "namespace": "ArticleCompoundNumber"
          }
        ],
        "Confidence": [
          {
            "identifier": "High",
            "namespace": "Confidence"
          }
        ],
        "Page": [
          {
            "identifier": "899",
            "namespace": "Page"
          }
        ]
      },
      "citation": {
        "article_type": "Journal Article",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "identifier": "22791904",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "namespace": "pubmed",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": "In addition, Posiphen significantly reduced levels of t-s (\u000174.1%, as assessed by the Innogenetics assay and \u000146.2%, as assessed by the AlphaLisa assay) and p-s (\u000161%, as assessed by the Innogenetics assay).",
      "key": "abbe2ae068750e35e53282390da37607",
      "line": 125,
      "relation": "decreases",
      "source": 0,
      "target": 8
    },
    {
      "annotations": {
        "ArticleCompoundNumber": [
          {
            "identifier": "1",
            "namespace": "ArticleCompoundNumber"
          }
        ],
        "Confidence": [
          {
            "identifier": "High",
            "namespace": "Confidence"
          }
        ],
        "Page": [
          {
            "identifier": "899",
            "namespace": "Page"
          }
        ]
      },
      "citation": {
        "article_type": "Journal Article",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "identifier": "22791904",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "namespace": "pubmed",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": " A significant lowering of pro-inflammatory, C3 (\u000186.9%) and microglial activation markers, MCP-1 (\u000187.5%) and YKL-40 (\u000172.7%), was evident.",
      "key": "705d99a9b00eb08e493bf2959815b025",
      "line": 130,
      "relation": "decreases",
      "source": 0,
      "target": 3
    },
    {
      "annotations": {
        "ArticleCompoundNumber": [
          {
            "identifier": "1",
            "namespace": "ArticleCompoundNumber"
          }
        ],
        "Confidence": [
          {
            "identifier": "High",
            "namespace": "Confidence"
          }
        ],
        "Page": [
          {
            "identifier": "899",
            "namespace": "Page"
          }
        ]
      },
      "citation": {
        "article_type": "Journal Article",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "identifier": "22791904",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "namespace": "pubmed",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": " A significant lowering of pro-inflammatory, C3 (\u000186.9%) and microglial activation markers, MCP-1 (\u000187.5%) and YKL-40 (\u000172.7%), was evident.",
      "key": "adfcb6f9129a2408c1e5e98ae029398e",
      "line": 131,
      "relation": "decreases",
      "source": 0,
      "target": 4
    },
    {
      "annotations": {
        "ArticleCompoundNumber": [
          {
            "identifier": "1",
            "namespace": "ArticleCompoundNumber"
          }
        ],
        "Confidence": [
          {
            "identifier": "High",
            "namespace": "Confidence"
          }
        ],
        "Page": [
          {
            "identifier": "899",
            "namespace": "Page"
          }
        ]
      },
      "citation": {
        "article_type": "Journal Article",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "identifier": "22791904",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "namespace": "pubmed",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": " A significant lowering of pro-inflammatory, C3 (\u000186.9%) and microglial activation markers, MCP-1 (\u000187.5%) and YKL-40 (\u000172.7%), was evident.",
      "key": "caa9244cff4acb0aeab4cfd33047e051",
      "line": 132,
      "relation": "decreases",
      "source": 0,
      "target": 6
    },
    {
      "annotations": {
        "ArticleCompoundNumber": [
          {
            "identifier": "1",
            "namespace": "ArticleCompoundNumber"
          }
        ],
        "Confidence": [
          {
            "identifier": "High",
            "namespace": "Confidence"
          }
        ],
        "Page": [
          {
            "identifier": "899",
            "namespace": "Page"
          }
        ]
      },
      "citation": {
        "article_type": "Journal Article",
        "authors": [
          "Chang MY",
          "Greig NH",
          "John V",
          "Maccecchini ML",
          "Pan C",
          "Zetterberg H"
        ],
        "date": "2012-09-01",
        "first": "Maccecchini ML",
        "identifier": "22791904",
        "journal": "Journal of neurology, neurosurgery, and psychiatry",
        "last": "Greig NH",
        "name": "Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.",
        "namespace": "pubmed",
        "pages": "894-902",
        "volume": "83"
      },
      "evidence": "and the complement control protein, factor H, were unaffected by Posiphen (\u000126.1% and +23.7%, respectively).",
      "key": "7204597b93ce8dfcf29a223d3429d3f2",
      "line": 137,
      "relation": "causesNoChange",
      "source": 0,
      "target": 5
    },
    {
      "key": "080972dc80c9f38e1b7d1f7bc3b27b25",
      "relation": "hasVariant",
      "source": 7,
      "target": 8
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(PUBCHEM:11249342)",
      "concept": {
        "name": "11249342",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "0a63bb4c27cfcfd8a51a997280b57bac"
    },
    {
      "bel": "p(CONSO:sAPP-alpha)",
      "concept": {
        "name": "sAPP-alpha",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "26e8e9b26633c7c3bf3b02e525ee9b53"
    },
    {
      "bel": "p(CONSO:sAPP-beta)",
      "concept": {
        "name": "sAPP-beta",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "8ef47d62cc07482a6b7e8f008be64c82"
    },
    {
      "bel": "p(HGNC:C3)",
      "concept": {
        "name": "C3",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "26a8a2f1cb63e49c899e482f0bcf01f3"
    },
    {
      "bel": "p(HGNC:CCL2)",
      "concept": {
        "name": "CCL2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "2a1fddd8526478c2c7edadaa639bbe85"
    },
    {
      "bel": "p(HGNC:CFH)",
      "concept": {
        "name": "CFH",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "afb9aa5abfd9d2c6fd6d71af95794009"
    },
    {
      "bel": "p(HGNC:CHI3L1)",
      "concept": {
        "name": "CHI3L1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "17cc90471d0859ee3991ac6970983309"
    },
    {
      "bel": "p(HGNC:MAPT)",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7d1009217050e75d549c8c5aa83309a8"
    },
    {
      "bel": "p(HGNC:MAPT, pmod(go:0006468 ! \"protein phosphorylation\"))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "f12d372e20d49c261fa134ab17d23cdd",
      "variants": [
        {
          "concept": {
            "identifier": "0006468",
            "name": "protein phosphorylation",
            "namespace": "go"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "path(MESH:Nausea)",
      "concept": {
        "name": "Nausea",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "41e2b9e6454d4c63a3654236ce97040f"
    },
    {
      "bel": "path(MESH:Vomiting)",
      "concept": {
        "name": "Vomiting",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "364ae88ab20bb2e8a9fd696110a8f558"
    }
  ]
}